Wednesday, September 23, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1semaglutidenaionwegovycase reportophthalmology

Case report describes NAION after 40 kg loss on semaglutide in 42-year-old

The Korean Journal of Family Medicine report involves a man with diabetes, hypertension, dyslipidemia and smoking history who lost the weight over two months.

MH
By Maren Holt · Senior Reporter, GLP-1
Aug 31 20:00 ETSource: Korean journal of family medicine

The wire

  1. 01A 42-year-old man on Wegovy developed acute right-eye visual disturbance with optic disc edema and an inferior field defect; imaging and labs found no other cause.
  2. 02Semaglutide was stopped and high-dose intravenous methylprednisolone given; at six months disc edema resolved with mild pallor but the visual field defect persisted.
  3. 03The authors state causality cannot be established from a single case and urge vigilance for optic neuropathy, particularly with rapid weight loss and vascular risk factors.

From the source

Nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy: a case report

Korean journal of family medicine · 2026 Sep · Cho CH, Kim WJ et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →